Skip to main content

Table 1 Demographics and laboratory data of screened patients in the WRHI001 South African Cohort

From: Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial

Variable Proportion or central measure
Population demographics and health status
Female n (%) 432 (57%)
Mean age (sd) 33.9 (7.7)
Nationality n (%)
 South African 431 (57%)
 Zimbabwean 287 (38%)
 Other African countries 40 (5%)
Marital status n (%)
 Married 174 (24%)
 Divorced or separate 12 (2%)
 Single 554 (75%)
Employed n (%) 551 (75%)
Current alcohol use n (%) 269 (36%)
Current smoking n (%) 116 (16%)
WHO clinical stage
 I 433 (59%)
 II 164 (22%)
 III 119 (16%)
 IV 20 (3%)
Median CD4 cells/μL at screening (IQR), n = 755a 208 (118-299)
Median plasma viral load copies/mL (IQR) 64,782 (17,646–186,662)
Laboratory screening tests prior to antiretroviral treatment
Creatinine clearance n < 50 mL/min (%) 4 (1%)
Microalbumin-to-creatinine ratio mg/mmol n (%)
 3.4–33.9 40 (5%)
  > 34.0 2 (0%)
Urine dipstick n (%)
 Proteinuria 1+ 60 (8%)
 Proteinuria 2+ 14 (2%)
 Proteinuria 3+ 7 (1%)
Hepatitis B surface antigen positive n (%) 60 (8%)
Abnormal ALT/AST IU/L n (%) in all patients
 40–99 (1-2.4 X normal) 145 (19%)
 100–199 (2.5-4.9 X normal) 22 (3%)
  ≥ 200 (≥5 X normal) 4 (1%)
Abnormal ALT/AST IU/L n (%) If hepatitis B positive
 40–99 19 (32%)
 100–199 2 (3%)
  ≥ 200 2 (3%)
Anaemia in females n (%)
 8–10.0 g/dL 40 (9%)
  < 8.0 g/dL 10 (2%)
Anaemia in males n (%)  
 8–10.0 g/dL 13 (4%)
  < 8.0 g/dL 2 (1%)
Neutrophil count
  < 0.75 × 10^9 /L n (%) 7 (1%)
 Median cells (IQR) 2.2 (1.6-2.9)
Platelet counts (cells/μl) n (%)
  < 50,000 3 (0)
 50,000--125,000 25 (3)
  1. a16 patients were excluded from the trial for reasons other than CD4 count, and thus CD4 tests were not done. IQR - inter-quartile range. sd - standard deviation